Blog Read the latest perspectives from our team of subject matter experts and others How Incyte Is Advancing Clinical Trial DiversityDiversity in clinical trials is more than just a regulatory requirement—it’s a critical component of equitable healthcare. Ensuring that trial participants reflect the real-world patient population leads to more… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research KOL EngagementComplying with MSL RegulationsMedical Science Liaisons (MSLs) are members of the Medical Affairs departments in pharmaceutical companies and have a wide range of responsibilities. An important part of the MSL role is… Continue reading → Read the article KOL EngagementMSL Conduct Dos and Don’tsMedical Science Liaisons (MSLs) are in the field (almost) every day and so are their field-based commercial colleagues, specifically sales representatives. Although they interact with the same people, healthcare… Continue reading → Read the article KOL EngagementPayer Mix: Understanding How Patients Receive Care and Who Pays for itTo find out which healthcare providers (HCPs) are actively treating patients in a therapeutic area, you’ll want access to more than just publication information. To really dig in, you… Continue reading → Read the article KOL EngagementAnnouncing A New Way to Identify KOLs with Claims DataPublications can only get you so far. If your medical affairs team really wants to know who’s actively treating patients in a therapeutic area, you need access to claims data.… Continue reading → Read the article KOL EngagementThe Importance of an Integrated KOL Engagement StrategyBuilding long-term, mutually beneficial relationships with external stakeholders such as physicians, key opinion leaders (KOLs) and other experts is the ultimate goal of medical affairs, specifically medical science liaisons (MSLs).… Continue reading → Read the article CommercializationMedical Nanotechnology: What’s Real & What’s NotSince Elon Musk’s tweet characterizing nanotech as “BS,” there’s been a continuing debate about the practical applications of nanotechnology — and where the dividing line between innovation and hype lies. Medical nanotechnology,… Continue reading → Read the article«‹12131415161718›»
